

Variable	Total	Continuous-KRG	Placebo-KRG	p value
SjS patients (n = $77$ ) <sup>a)</sup>				
ESSPRI, OW	60.0 (50.0 to 67.0)	60.0 (50.0 to 67.0)	60.0 (52.2 to 67.0)	0.842
ESSPRI, 12W	50.0 (38.5 to 58.5)	47.0 (37.0 to 60.0)	50.0 (40.8 to 53.0)	0.853
∆ESSPRI (12W)	10.0 (0.0 to 20.0)	7.0 (-3.0 to 20.0)	10.0 (0.8 to 19.2)	0.782
ESSPRI, 24W	47.0 (33.0 to 57.0)	47.0 (37.0 to 60.0)	45.0 (33.0 to 56.0)	0.477
∆ESSPRI (24W)	13.0 (1.5 to 23.5)	10.0 (0.0 to 23.0)	14.0 (6.2 to 24.0)	0.365
RA patients $(n = 43)^{a}$				
DAS28-ESR, OW	3.4 (2.6 to 4.1)	3.4 (2.7 to 4.5)	3.3 (2.3 to 4.0)	0.361
DAS28-ESR, 12W	3.4 (2.5 to 3.9)	3.5 (3.1 to 4.0)	3.1 (2.3 to 3.5)	0.033
∆DAS28-ESR (12W)	0.1 (-0.5 to 0.8)	0.0 (-0.7 to 0.8)	0.1 (-0.4 to 0.6)	0.356
DAS28-ESR, 24W	3.3 (2.4 to 4.0)	3.5 (2.6 to 4.0)	3.0 (2.0 to 4.0)	0.172
∆DAS28-ESR (24W)	0.3 (-0.5 to 0.8)	0.5 (-0.7 to 0.9)	0.2 (-0.3 to 0.8)	0.925

## Supplementary Table1. Comparison of disease activity between treatment groups according to underlying disease (per protocol analysis)

Values were presented as median (interquartile range).

KRG, Korean Red Ginseng; SjS, Sjogren's syndrome; ESSPRI, EULAR Sjogren's Syndrome Patient Reported Index; RA, rheumatoid arthritis; DAS28-ESR, Disease Activity Score of 28 joints-erythrocyte sedimentation rate.

<sup>a)</sup>ESSPRI was measured for patients with Sjogren's syndrome and both diseases, and DAS28-ESR for RA patients.